SCHEMBL25617599

SCHEMBL25617599

CCCN(CCOS(C)(=O)=O)c1ccc([N+](=O)[O-])cc1S(=O)(=O)N1CCN(C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
HTT P42858 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2C19 P33261 2/20 0.49
MAPT P10636 2/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HPGD P15428 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
CYP19A1 P11511 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25617637 0.96 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL21410445 0.96 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL25617642 0.94 L3MBTL1 (0.46) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL23245063 0.93 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL21410815 0.93 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL25617602 0.92 MAPT (0.48) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL21410329 0.92 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL21416253 0.90 L3MBTL1 (0.49) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL25617604 0.90 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2HTTCYP1A2CYP3A4
SCHEMBL25617651 0.90 HTT (0.49) ALDH1A1SMN1; SMN2HTTCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661404-B2 Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders ACHILLES MEDICAL LIMITED (NZ) 2023-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661404-B2 Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders AKR1C2, AKR1C1, AKR1B1 ALDH1A1 61/4885SMN1; SMN2 4208/4885HTT 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.